



Anion inhibition studies of the Zn(II)-bound L-carbonic anhydrase from the Gram-negative bacterium *Burkholderia territorii*

Andrea Petreni, Viviana De Luca, Andrea Scaloni, Alessio Nocentini, Clemente Capasso & Claudiu T. Supuran

To cite this article: Andrea Petreni, Viviana De Luca, Andrea Scaloni, Alessio Nocentini, Clemente Capasso & Claudiu T. Supuran (2021) Anion inhibition studies of the Zn(II)-bound L-carbonic anhydrase from the Gram-negative bacterium *Burkholderia territorii*, Journal of Enzyme Inhibition and Medicinal Chemistry, 36:1, 372-376, DOI: [10.1080/14756366.2020.1867122](https://doi.org/10.1080/14756366.2020.1867122)

To link to this article: <https://doi.org/10.1080/14756366.2020.1867122>



© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.



Published online: 04 Jan 2021.



Submit your article to this journal [↗](#)



Article views: 1770



View related articles [↗](#)



View Crossmark data [↗](#)




Citing articles: 13 View citing articles [↗](#)

RESEARCH PAPER



Anion inhibition studies of the Zn(II)-bound ι -carbonic anhydrase from the Gram-negative bacterium *Burkholderia territorii*

Andrea Petreni^a, Viviana De Luca^{b,c}, Andrea Scaloni^c, Alessio Nocentini^a , Clemente Capasso^b  and Claudiu T. Supuran^a 

^aDepartment of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Polo Scientifico, Firenze, Italy; ^bDepartment of Biology, Agriculture and Food Sciences, CNR, Institute of Biosciences and Bioresources, Napoli, Italy; ^cProteomics and Mass Spectrometry Laboratory, ISPAAM, CNR, Naples, Italy

ABSTRACT

Burkholderia territorii, a Gram-negative bacterium, encodes for the ι -class carbonic anhydrase (CA, EC 4.2.1.1) BteCA ι , which was recently characterised. It acts as a good catalyst for the hydration of CO₂ to bicarbonate and protons, with a k_{cat} value of $3.0 \times 10^5 \text{ s}^{-1}$ and $k_{\text{cat}}/K_{\text{M}}$ value of $3.9 \times 10^7 \text{ M}^{-1} \text{ s}^{-1}$. No inhibition data on this new class of enzymes are available to date. We report here an anion and small molecules inhibition study of BteCA ι , which we prove to be a zinc(II)- and not manganese(II)-containing enzyme, as reported for diatom ι -CAs. The best inhibitors were sulphamic acid, stannate, phenylarsonic acid, phenylboronic acid and sulfamide (K_{i} values of 6.2–94 μM), whereas diethyldithiocarbamate, tellurate, selenate, bicarbonate and cyanate were submillimolar inhibitors (K_{i} values of 0.71–0.94 mM). The halides (except iodide), thiocyanate, nitrite, nitrate, carbonate, bisulphite, sulphate, hydrogensulfide, peroxydisulfate, selenocyanate, fluorosulfonate and trithiocarbonate showed K_{i} values in the range of 3.1–9.3 mM.

ARTICLE HISTORY

Received 13 November 2020
Revised 12 December 2020
Accepted 16 December 2020

KEYWORDS





Carbonic anhydrase; ι -class;
anion; inhibitor;
Burkholderia territorii

1. Introduction

The carbonic anhydrase (CA, EC 4.2.1.1) superfamily is composed nowadays of eight genetically distinct classes, the α -, β -, γ -, δ -, ζ -, η -, θ -, and ι -CAs, which probably may soon increase when additional families will be reported in other organisms. All of them catalyse a simple but physiologically crucial reaction, the carbon dioxide reversible hydration to bicarbonate and protons $\text{CO}_2 + \text{H}_2\text{O} \rightleftharpoons \text{HCO}_3^- + \text{H}^+$. CO₂ hydration/bicarbonate dehydration are relevant in organisms all over the phylogenetic tree, from simple to complex ones. In most cells, tissues and organs, these enzymes participate in crucial physiologic processes connected to pH regulation, metabolism, secretion of electrolytes, transport of gases and anions, and others, which are also therapeutically relevant (at least for mammals)^{5,7,8}. In fact, both CA inhibitors (CAIs)^{5–8}, and CA activators (CAAs)^{9,10} have many therapeutic applications in a variety of fields, starting with diuretics and anti-glaucoma agents and ending with anticancer/antimetastatic drugs (for the inhibitors)^{5–8}, but also including memory therapy, modulation of emotional memory and fear extinction memory activator agents^{9,10}. Recently, inhibition of CAs from pathogenic organisms has also been proposed as an innovative approach to develop anti-infectives, which may target bacterial infections resistant to clinically used antibiotics^{4,11–13}, but also to treat protozoan-provoked^{14,15} as well as fungal infections^{16,17}. Indeed, various classes of inhibitors were shown to be effective in a variety of models^{4,11–17}, which inspired researchers to find novel chemotypes

acting as modulators of activity as well as novel potential drug targets^{4,11–17}.

Very recently, a gene coding for a member of the ι -CA family has been originally described to occur in the genome of the marine diatom *Thalassiosira pseudonana*^{2a}; the corresponding enzyme has been isolated and reported preferring Mn(II) as a metal cofactor in its active site, and not Zn(II) frequently found therein in other organisms. In the same paper, it has been shown that members of the ι -CA family should be present also in bacteria, as deduced by genome analysis, although such enzymes were not characterised at that moment in such organisms. Recently, we confirmed the finding of Gontero's group^{2a}, and reported the cloning and biochemical characterisation of the first example of a bacterial ι -CA, which was observed in the Gram-negative bacterium *Burkholderia territorii* and denominated BteCA ι ^{2b}. The enzyme showed a significant CO₂ hydrase activity, with kinetic parameters (k_{cat} of $3.0 \times 10^5 \text{ s}^{-1}$ and $k_{\text{cat}}/K_{\text{M}}$ of $3.9 \times 10^7 \text{ M}^{-1} \text{ s}^{-1}$) comparable to those of highly efficient bacterial and even mammalian isoforms, such as human (h) CA I^{2b}. However, no inhibition studies have been performed so far on this enzyme, which has been demonstrated to be dimeric (by using protonography)¹⁸ and also to be a zinc- and not manganese-dependent enzyme^{2b}. Here, we prove that this is indeed the case by using atomic absorption spectroscopy, and also report the first inhibition study of the enzyme, with small molecules and anions, a well-known class of CAIs¹⁹.

CONTACT Clemente Capasso  clemente.capasso@ibbr.cnr.it  Department of Biology, Agriculture and Food Sciences, CNR, Institute of Biosciences and Bioresources, Via Pietro Castellino 111, Napoli, 80131, Italy; Claudiu T. Supuran  claudiu.supuran@unifi.it  Department of NEUROFARBA, University of Florence, Section of Pharmaceutical and Nutraceutical Sciences, Polo Scientifico, Via U. Schiff 6, Sesto Fiorentino, Firenze, 50019, Italy

© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Table 1. Percentage of zinc and manganese in BteCA_I as determined by atomic absorption spectroscopy.

Enzyme	Concentration (μM)	% Zn-BteCA _I	% Mn-BteCA _I
Zn-BteCA _I – sample 1	33.5	98.30	1.70
Zn-BteCA _I – sample 2	46.6	99.93	0.07
Mn-BteCA _I – sample 1	20.0	97.85	2.15
Mn-BteCA _I – sample 2	21.0	99.74	0.26

The buffer used for sample preparation reported 7.0×10^{-3} ppm of Zn and 1.1×10^{-2} ppm of Mn.

2. Materials and methods

2.1. Chemistry

Anions and small molecules were commercially available reagents of the highest available purity from Sigma-Aldrich (Milan, Italy). Purity of tested compounds was higher than 99%.

2.2. Atomic absorption spectrometry

In various enzyme samples, the content of Zn(II) and Mn(II) was measured with a flame PinAAcle 500 Perkin Elmer instrument, located in the Interdepartmental Service Centre for Biotechnology of Agricultural, Chemical and Industrial Interest (CIBIACI), University of Florence.

2.3. Enzymology

BteCA_I was a recombinant enzyme obtained in-house as described earlier^{2b}.

2.4. Ca catalytic activity and inhibition assay

An Applied Photophysics stopped-flow instrument has been used for assaying the CA catalysed CO₂ hydration activity²⁰. Phenol red (at a concentration of 0.2 mM) has been used as an indicator, working at the absorbance maximum of 557 nm, with 10–20 mM HEPES (pH 7.5) as buffers, and 20 mM NaClO₄ (for maintaining constant the ionic strength), following the initial rates of the CA-catalysed CO₂ hydration reaction for a period of 10–100 s. The CO₂ concentrations ranged from 1.7 to 17 mM for the determination of the kinetic parameters and inhibition constants. For each inhibitor, at least six traces of the initial 5–10% of the reaction were used to determine the initial velocity. The uncatalyzed rates were determined in the same manner and subtracted from the total observed rates. Stock solutions of inhibitors (10 mM) and dilutions up to 0.01 μM were prepared in distilled-deionised water. Inhibitor and enzyme solutions of concentrations ranging between 5 and 10 nM were preincubated together for 15 min, at room temperature, prior to assay, in order to allow for the E-I complex formation. The inhibition constants were obtained by non-linear least-squares methods using PRISM 3 and the Cheng-Prusoff equation, as reported earlier²¹, and represent the mean from at least three different determinations.

3. Results and discussion

Gontero's group reported that the *l*-CA isolated from the marine diatom *T. pseudonana*^{2a} is active with Mn(II) bound as a metal cofactor within its active site and not with Zn(II), such as most other CA isoforms known to date. However, it should be mentioned that γ -CAs are active with Fe(II)²² and ζ -CAs with Cd(II)²³ present at their active sites, as well as with Zn(II), so that the use of alternative metal ions to zinc is not improbable. Thus, we

Table 2. Anion inhibition data of BteCA_I as determined by a stopped-flow CO₂ hydrase assay.²⁰

Anion	K _i (mM) ^a			
	hCA I ^b	hCA II ^b	<i>E. coli</i> β-CA ^c	BteCA _I ^d
F ⁻	>300	>300	9.4	4.6
Cl ⁻	6	200	6.7	3.1
Br ⁻	4	63	3.8	4.8
I ⁻	0.3	26	>50	>50
CNO ⁻	0.0007	0.03	0.58	0.79
SCN ⁻	0.2	1.6	5.7	6.1
CN ⁻	0.0005	0.02	>50	>50
N ₃ ⁻	0.0012	1.51	>50	>50
NO ₂ ⁻	8.4	63	4.9	8.4
NO ₃ ⁻	7	35	2.4	6.2
HCO ₃ ⁻	12	85	0.81	0.94
CO ₃ ²⁻	15	73	0.89	4.4
HSO ₃ ⁻	18	89	3.7	8.4
SO ₄ ²⁻	63	>200	1.7	5.8
HS ⁻	0.0006	0.04	2.7	6.2
NH ₂ SO ₂ NH ₂	0.31	1.13	0.011	0.086
NH ₂ SO ₃ H	0.021	0.39	0.0025	0.0062
PhAsO ₃ H ₂	31.7	49	0.0061	0.008
PhB(OH) ₂	58.6	23	0.0028	0.009
ClO ₄ ⁻	>200	>200	>50	>50
SnO ₃ ²⁻	0.57	0.83	0.52	0.094
SeO ₄ ²⁻	118	112	3.1	0.73
TeO ₄ ²⁻	0.66	0.92	0.51	0.71
OsO ₅ ²⁻	0.92	0.95	>50	>50
P ₂ O ₇ ²⁻	25.8	48	>50	>50
V ₂ O ₇ ²⁻	0.54	0.57	>50	>50
B ₄ O ₇ ²⁻	0.64	0.95	0.25	>50
ReO ₄ ⁻	0.11	0.75	>50	>50
RuO ₄ ⁻	0.101	0.69	9.5	>50
S ₂ O ₈ ²⁻	0.107	0.084	6.4	7.4
SeCN ⁻	0.085	0.086	3.1	6.6
NH(SO ₃) ₂ ²⁻	0.31	0.76	1.5	>50
FSO ₃ ⁻	0.79	0.46	0.83	9.3
CS ₃ ²⁻	0.0087	0.0088	3.1	8.6
EtNCS ₂ ⁻	0.00079	0.0031	0.084	0.81
PF ₆ ⁻	>50	>50	>50	>50
CF ₃ SO ₃ ⁻	>50	>50	>50	>50

Inhibition of the human isoforms hCA I and II, and the bacterial β-CA from *Escherichia coli* are also shown for comparison.

^aMean from 3 different assays, by a stopped flow technique (errors were in the range of ± 5–10% of the reported values).

^bFrom Ref. ¹⁹.

^cFrom Ref. ²⁴.

^dThis work.

prepared the recombinant BteCA_I as described earlier^{2b}, both in the presence of zinc as well as manganese salts in order to assay which of the two metal ions are incorporated into the holoenzyme. As seen from Table 1, significant amounts of Zn(II) were found in all protein samples investigated, with trace quantities of Mn(II). The amount of Mn(II) was the same in both enzyme samples, even those prepared in the presence of high concentrations of Mn(II) salts (possibly due to contaminants in the buffers/reagents used to prepare the enzyme). The content of zinc ion per polypeptide chain was determined as 1:1 (within experimental error limits). Hence, unlike the diatom enzyme^{2a}, the bacterial *l*-CA was proved to be a zinc-containing enzyme.

We also investigated the inhibition of the bacterial enzyme BteCA_I with a wide range of inorganic anions and small molecule compounds known to interact with the CA family of proteins (Table 2)¹⁹. Although anion inhibitors are usually not highly effective, they are relevant both for understanding in detail the inhibition mechanisms of metalloenzymes and for drug design purposes; this was the reason why many CAs belonging to various families were profiled for their inhibition with anions¹⁹.

The data of Table 2 show the following interesting aspects for the inhibition of this poorly investigated CA class:

- i. some anions, among which iodide, cyanide, azide, perchlorate, perosmate, diphosphate, divanadate, tetraborate, perrhenate, perruthenate, iminodisulfonate, hexafluorophosphate and trifluoromethanesulfonate, did not inhibit BteCA_I significantly up to 50 mM concentration of inhibitor in the assay system. This is not unexpected for anions with low affinity for complexing metal ions, such as perchlorate, hexafluorophosphate and trifluoromethanesulfonate¹⁹, but it is rather surprising for iodide, cyanide, and azide, which have quite a high affinity for metal ions in solution and in the active site of many metalloenzymes¹⁹. Indeed, some of these anions show a potent inhibitory action for other CAs, such as the isoform hCA I (Table 1 and Ref. 19). As no X-ray crystallographic data are available so far for *ι*-CAs, it is impossible to rationalise these interesting and surprising data.
- ii. The following inhibitors showed inhibitory action against BteCA_I in the millimolar range: fluoride, chloride, bromide, thiocyanate, nitrite, nitrate, carbonate, bisulphite, sulphate, hydrogensulfide, peroxydisulfate, selenocyanate, fluorosulfonate and trithiocarbonate (KI values in the range of 3.1–9.3 mM). As above, some of these data stupefied us: sulphate, for example, is a highly inefficient inhibitor of many α -CAs (e.g. hCA I and II), but it inhibits efficiently the bacterial β - and *ι*-CAs shown in Table 1.
- iii. Even more efficient inhibitory action against BteCA_I was registered for the following anions: diethyldithiocarbamate, tellurate, selenate, bicarbonate and cyanate, which were submillimolar inhibitors with KI values ranging between 0.71 and 0.94 mM (Table 1). The bicarbonate high affinity is of interest, since this anion is also a substrate/reaction product of the CA – catalysed reactions.
- iv. The most efficient BteCA_I inhibitors detected so far were stannate, sulphamic acid, phenylarsonic acid, phenylboronic acid and sulfamide, with KI values of 6.2–94 μ M (Table 1). Some of these compounds, such as sulfamide and sulphamic acid, act as effective inhibitors of many other CAs (for example, see the *E. coli* β -CA inhibition data shown in Table 1). They also inhibit the human isoforms hCA I and II (although to lower levels compared to the bacterial enzymes). The stannate data is also quite interesting. This anion is an order of magnitude better as a BteCA_I inhibitor compared to its inhibition level of other CAs investigated so far.

4. Conclusions

We investigated the nature of the metal ion within the active site of the first bacterial *ι*-CA described so far, namely BteCA_I, whose corresponding gene was found in the genome of the Gram-negative bacterium *B. territorii*. Unlike the diatom enzyme cloned from *T. pseudonana*, the bacterial *ι*-CA has Zn(II) ions at its active site and not Mn(II) counterparts. We also report here the first inhibition study of BteCA_I with a range of inorganic anions and small molecules known to act as CA inhibitors. The most efficient BteCA_I inhibitors were stannate, sulphamic acid, phenylarsonic acid, phenylboronic acid and sulfamide, with K_I values of 6.2–94 μ M. Diethyldithiocarbamate, tellurate, selenate, bicarbonate and cyanate were submillimolar inhibitors, with K_Is ranging between 0.71 and 0.94 mM. Fluoride, chloride, bromide, thiocyanate, nitrite, nitrate, carbonate, bisulphite, sulphate,

hydrogensulfide, peroxydisulfate, selenocyanate, fluorosulfonate and trithiocarbonate showed K_I values in the range of 3.1–9.3 mM, whereas no inhibition was registered for iodide, cyanide, azide, perchlorate, perosmate, diphosphate, divanadate, tetraborate, perrhenate, perruthenate, iminodisulfonate, hexafluorophosphate and trifluoromethanesulfonate. These data may be useful for designing more efficient *ι*-CA inhibitors.

Acknowledgements

The authors are grateful to Giovanni Del Monaco (CNR-IBBR) for technical assistance.

Disclosure statement

The authors declare no conflict of interest.

ORCID

Alessio Nocentini  <http://orcid.org/0000-0003-3342-702X>

Clemente Capasso  <http://orcid.org/0000-0003-3314-2411>

Claudiu T. Supuran  <http://orcid.org/0000-0003-4262-0323>

References

1. (a) Supuran CT. Structure and function of carbonic anhydrases. *Biochem J* 2016;473:2023–32. (b) Capasso C, Supuran CT. An overview of the alpha-, beta- and gamma-carbonic anhydrases from Bacteria: can bacterial carbonic anhydrases shed new light on evolution of bacteria? *J Enzyme Inhib Med Chem* 2015;30:325–32. (c) Mishra CB, Tiwari M, Supuran CT. Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: where are we today? *Med Res Rev* 2020;40:2485–565.
2. (a) Jensen EL, Clement R, Kosta A, et al. A new widespread subclass of carbonic anhydrase in marine phytoplankton. *Isme J* 2019;13:2094–106. (b) Del Prete S, Nocentini A, Supuran CT, Capasso C. Bacterial *ι*-carbonic anhydrase: a new active class of carbonic anhydrase identified in the genome of the Gram-negative bacterium *Burkholderia territorii*. *J Enzyme Inhib Med Chem* 2020;35:1060–8.
3. (a) Ozensoy Guler O, Capasso C, Supuran CT. A magnificent enzyme superfamily: carbonic anhydrases, their purification and characterization. *J Enzyme Inhib Med Chem* 2016;31: 689–94. (b) Kikutani S, Nakajima K, Nagasato C, et al. Thylakoid luminal theta-carbonic anhydrase critical for growth and photosynthesis in the marine diatom *Phaeodactylum tricorutum*. *Proc Natl Acad Sci U S A* 2016; 113:9828–33. (c) Jin S, Vullo D, Bua S, et al. Structural and biochemical characterization of novel carbonic anhydrases from *Phaeodactylum tricorutum*. *Acta Crystallogr D Struct Biol* 2020;76:676–86. (d) Del Prete S, Bua S, Supuran CT, Capasso C. *Escherichia coli* γ -carbonic anhydrase: characterisation and effects of simple aromatic/heterocyclic sulphamide inhibitors. *J Enzyme Inhib Med Chem* 2020;35: 1545–54.
4. (a) Capasso C, Supuran CT. Bacterial, fungal and protozoan carbonic anhydrases as drug targets. *Expert Opin Ther Targets* 2015;19:1689–704. (b) Supuran CT, Capasso C. The eta-class carbonic anhydrases as drug targets for antimalarial agents. *Expert Opin Ther Targets* 2015;19:551–63. (c) Supuran CT, Capasso C. Antibacterial carbonic anhydrase

- inhibitors: an update on the recent literature. *Expert Opin Ther Pat* 2020.
5. (a) Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. *Nat Rev Drug Discov* 2008;7:168–81. (b) Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. *Nat Rev Drug Discov* 2011; 10:767–77. (c) Supuran CT. Carbonic anhydrases and metabolism. *Metabolites* 2018; 8:25. (d) Supuran CT. Exploring the multiple binding modes of inhibitors to carbonic anhydrases for novel drug discovery. *Expert Opin Drug Discov* 2020;15:671–86.
 6. (a) Urbański LJ, Di Fiore A, Azizi L, et al. Biochemical and structural characterisation of a protozoan beta-carbonic anhydrase from *Trichomonas vaginalis*. *J Enzyme Inhib Med Chem* 2020;35:1292–9. (b) Nocentini A, Supuran CT. Advances in the structural annotation of human carbonic anhydrases and impact on future drug discovery. *Expert Opin Drug Discov* 2019; 14:1175–97. (c) Supuran CT. Structure-based drug discovery of carbonic anhydrase inhibitors. *J. Enzyme Inhib. Med. Chem* 2012; 27:759–72. (d) Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? *J Enzyme Inhib Med Chem* 2016; 31:345–60.
 7. (a) Alterio V, Di Fiore A, D'Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? *Chem Rev* 2012; 112:4421–68. (b) Angeli A, Carta F, Nocentini A, et al. Carbonic anhydrase inhibitors targeting metabolism and tumor microenvironment. *Metabolites* 2020;10:412. (c) Supuran CT, Alterio V, Di Fiore A, et al. Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: three for the price of one. *Med Res Rev* 2018;38: 1799–836.
 8. (a) Supuran CT. Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas. *Expert Opin Ther Pat* 2018;28:709–12. (b) Scozzafava A, Supuran CT, Carta F. Antiobesity carbonic anhydrase inhibitors: a literature and patent review. *Expert Opin Ther Pat* 2013; 23:725–35. (c) Di Cesare Mannelli L, Micheli L, Carta F, et al. Carbonic anhydrase inhibition for the management of cerebral ischemia: in vivo evaluation of sulfonamide and coumarin inhibitors. *Enzyme Inhib Med Chem* 2016;31:894–9. (d) Supuran CT, Altamimi ASA, Carta F. Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013–2019. *Expert Opin Ther Pat* 2019; 29:781–92. (e) Supuran CT. The management of glaucoma and macular degeneration. *Expert Opin Ther Pat* 2019; 29:745–7.
 9. (a) Supuran CT. Carbonic anhydrase activators. *Future Med Chem* 2018;10:561–73. (b) Blandina P, Provensi G, Passani MB, et al. Carbonic anhydrase 5. Implications for the treatment of cognitive disorders. *J Enzyme Inhib Med Chem* 2020;35:1206–14. (c) Nocentini A, Cuffaro D, Ciccone L, et al. Activation of carbonic anhydrases from human brain by amino alcohol oxime ethers: towards human carbonic anhydrase VII selective activators. *J Enzyme Inhib Med Chem* 2021;36:48–57.
 10. (a) Schmidt SD, Costa A, Rani B, et al. The role of carbonic anhydrases in extinction of contextual fear memory. *Proc Natl Acad Sci U S A* 2020;117:16000–8. (b) Canto de Souza L, Provensi G, Vullo D, et al. Carbonic anhydrase activation enhances object recognition memory in mice through phosphorylation of the extracellular signal-regulated kinase in the cortex and the hippocampus. *Neuropharmacology* 2017; 118:148–56.
 11. (a) Del Prete S, De Luca V, Bua S, et al. The effect of substituted benzene-sulfonamides and clinically licensed drugs on the catalytic activity of CynT2, a carbonic anhydrase crucial for *Escherichia coli* life cycle. *Int J Mol Sci* 2020; 21:4175. (b) Angeli A, Ferraroni M, Pinteala M, et al. Crystal structure of a tetrameric type II β -carbonic anhydrase from the pathogenic bacterium *Burkholderia pseudomallei*. *Molecules* 2020; 25: 2269. (c) Gitto R, De Luca L, Mancuso F, et al. Seeking new approach for therapeutic treatment of cholera disease via inhibition of bacterial carbonic anhydrases: experimental and theoretical studies for sixteen benzenesulfonamide derivatives. *J Enzyme Inhib Med Chem* 2019; 34:1186–92. (d) Angeli A, Pinteala M, Maier SS, et al. Inhibition of α -, β -, γ -, δ -, ζ - and η -class carbonic anhydrases from bacteria, fungi, algae, diatoms and protozoans with famotidine. *J Enzyme Inhib Med Chem* 2019; 34:644–50.
 12. (a) Capasso C, Supuran CT. An overview of the selectivity and efficiency of the bacterial carbonic anhydrase inhibitors. *Curr Med Chem* 2015;22:2130–9. (b) Capasso C, Supuran CT. An overview of the carbonic anhydrases from two pathogens of the oral cavity: *Streptococcus mutans* and *Porphyromonas gingivalis*. *Curr Top Med Chem* 2016;16: 2359–68.
 13. Kaur J, Cao X, Abutaleb NS, et al. Optimization of acetazolamide-based scaffold as potent inhibitors of vancomycin-resistant *Enterococcus*. *J Med Chem* 2020;63:9540–62.
 14. (a) D'Ambrosio K, Supuran CT, De Simone G. Are carbonic anhydrases suitable targets to fight protozoan parasitic diseases? *Curr Med Chem* 2018;25:5266–78. (b) Nocentini A, Osman SM, Almeida IA, et al. Appraisal of anti-protozoan activity of nitroaromatic benzenesulfonamides inhibiting carbonic anhydrases from *Trypanosoma cruzi* and *Leishmania donovani*. *J Enzyme Inhib Med Chem* 2019;34:1164–71. (c) da Silva Cardoso V, Vermelho AB, Ricci Junior E, et al. Antileishmanial activity of sulphonamide nanoemulsions targeting the β -carbonic anhydrase from *Leishmania* species. *J Enzyme Inhib Med Chem* 2018;33:850–7.
 15. (a) Vermelho AB, Rodrigues GC, Supuran CT. Why hasn't there been more progress in new Chagas disease drug discovery? *Expert Opin Drug Discov* 2020;15:145–58. (b) Angeli A, Etxebeste-Mitxeltoarena M, Sanmartín C, et al. Tellurides bearing sulfonamides as novel inhibitors of leishmanial carbonic anhydrase with potent antileishmanial activity. *J Med Chem* 2020;63:4306–14. (c) Vermelho AB, da Silva Cardoso V, Ricci Junior E, et al. Nanoemulsions of sulfonamide carbonic anhydrase inhibitors strongly inhibit the growth of *Trypanosoma cruzi*. *J Enzyme Inhib Med Chem* 2018;33: 139–46. (d) Vermelho AB, Capaci GR, Rodrigues IA, et al. Carbonic anhydrases from *Trypanosoma* and *Leishmania* as anti-protozoan drug targets. *Bioorg Med Chem* 2017;25: 1543–55.
 16. (a) Del Prete S, Vullo D, Ghobril C, et al. Cloning, purification, and characterization of a beta-carbonic anhydrase from *Malassezia restricta*, an opportunistic pathogen involved in dandruff and seborrheic dermatitis. *Int J Mol Sci* 2019;20: 2447. (b) Angeli A, Prete SD, Ghobril C, et al. Activation studies of the β -carbonic anhydrases from *Malassezia restricta* with amines and amino acids. *J Enzyme Inhib Med Chem* 2020;35:824–30.
 17. (a) Nocentini A, Vullo D, Del Prete S, et al. Inhibition of the β -carbonic anhydrase from the dandruff-producing fungus *Malassezia globosa* with monothiocarbamates. *J Enzyme Inhib Med Chem* 2017;32:1064–70. (b) Angiolella L, Carradori

- S, Maccallini C, et al. Targeting *Malassezia* species for novel synthetic and natural antidandruff agents. *Curr Med Chem* 2017;24:2392–412. (c) Hewitson KS, Vullo D, Scozzafava A, et al. Molecular cloning, characterization, and inhibition studies of a β -carbonic anhydrase from *Malassezia globosa*, a potential antidandruff target. *J Med Chem* 2012;55:3513–20.
18. (a) De Luca V, Del Prete S, Supuran CT, Capasso C. Protonography, a new technique for the analysis of carbonic anhydrase activity. *J Enzyme Inhib Med Chem* 2015;30:277–82. (b) Del Prete S, De Luca V, Supuran CT, Capasso C. Protonography, a technique applicable for the analysis of η -carbonic anhydrase activity. *J Enzyme Inhib Med Chem* 2015;30:920–4. (c) Del Prete S, De Luca V, Iandolo E, et al. Protonography, a powerful tool for analyzing the activity and the oligomeric state of the γ -carbonic anhydrase identified in the genome of *Porphyromonas gingivalis*. *Bioorg Med Chem* 2015;23:3747–50.
19. (a) De Simone G, Supuran CT. (In)organic anions as carbonic anhydrase inhibitors. *J Inorg Biochem* 2012;111:117–29. (b) Bertucci A, Moya A, Tambutté S, et al. Carbonic anhydrases in anthozoan corals – a review. *Bioorg Med Chem* 2013;21:1437–50.
20. Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. *J Biol Chem* 1971; 246:2561–73.
21. (a) Maresca A, Scozzafava A, Supuran CT. 8-Disubstituted-but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II in the low nanomolar/subnanomolar range. *Bioorg Med Chem Lett* 2010;20:7255–8. (b) Innocenti A, Gülçin I, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I–XV. *Bioorg Med Chem Lett* 2010;20:5050–3. (c) Supuran CT, Nicolae A, Popescu A. Carbonic anhydrase inhibitors. Part 35. Synthesis of Schiff bases derived from sulfanilamide and aromatic aldehydes: the first inhibitors with equally high affinity towards cytosolic and membrane-bound isozymes. *Eur J Med Chem* 1996; 31:431–8. (d) Beyza Öztürk Sarıkaya S, Gülçin İ, Supuran CT. Carbonic anhydrase inhibitors: Inhibition of human erythrocyte isozymes I and II with a series of phenolic acids. *Chem Biol Drug Des* 2010; 75:515–20.
22. (a) Tripp BC, Bell CB 3rd, Cruz F, et al. A role for iron in an ancient carbonic anhydrase. *J Biol Chem* 2004;279:6683–7. (b) Zimmerman SA, Ferry JG, Supuran CT. Inhibition of the archaeal β -class (Cab) and γ -class (Cam) carbonic anhydrases. *Curr Top Med Chem* 2007; 7:901–8.
23. (a) Xu Y, Feng L, Jeffrey PD, et al. Structure and metal exchange in the cadmium carbonic anhydrase of marine diatoms. *Nature* 2008;452:56–61. (b) Viparelli F, Monti SM, De Simone G, et al. Inhibition of the R1 fragment of the cadmium-containing zeta-class carbonic anhydrase from the diatom *Thalassiosira weissflogii* with anions. *Bioorg Med Chem Lett* 2010; 20:4745–8. (c) Alterio V, Langella E, Viparelli F, et al. Structural and inhibition insights into carbonic anhydrase CDCA1 from the marine diatom *Thalassiosira weissflogii*. *Biochimie* 2012; 94:1232–41.
24. Del Prete S, De Luca V, Nocentini A, et al. Anion inhibition studies of the beta-carbonic anhydrase from *Escherichia coli*. *Molecules* 2020;25:2564.